Radius Health, Inc.
Radius Health, Inc. (RDUS): 5 pipeline candidates · ~5 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.7 months
D/E -1.56 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for Radius Health, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$73.1M
Quarterly Burn
$60.6M
Runway
4.7 mo
Revenue
$58.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| abaloparatide-sc | Phase 3 |
| abaloparatide-td | Phase 3 |
| elacestrant | Phase 3 |
| rad011 | Preclinical |
| tymlos | Approved |
Frequently asked questions
How many drug candidates are in Radius Health, Inc.'s pipeline?
Radius Health, Inc. (RDUS) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Radius Health, Inc.'s lead drug candidate?
Radius Health, Inc.'s most advanced tracked candidate is abaloparatide-sc (Phase 3) for males with osteoporosis at high risk for fracture.
What is Radius Health, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Radius Health, Inc. has approximately 4.7 months of cash runway.
Get the full picture on Radius Health, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.